Improvement of mucocutaneous lesions of CMV and EBV following commencement of ART have been reported in the setting of advanced HIV infection. (48) Systemic antiviral therapy is indicated for CMV infection in immunocompromised patients, and may involve oral valganciclovir or intravenous ganciclovir for up to six weeks. Oral valganciclovir may be continued as secondary prophylaxis in cases of recurrent disease or in cases with CD4+ count below 100 cells/μL. (50)